Comparison of doxorubicin and weekly paclitaxel efficacy in metastatic angiosarcomas
Open Access
- 1 November 2011
- Vol. 118 (13) , 3330-3336
Abstract
BACKGROUND: Data regarding the role of anthracyclines and taxanes as first‐line treatments of metastatic angiosarcoma are limited.METHODS: Records of 117 metastatic angiosarcoma patients who were treated with either doxorubicin or weekly paclitaxel were reviewed.RESULTS: Seventy‐five patients (64%) were treated with weekly paclitaxel and 42 (36%) with single‐agent doxorubicin. Patients in the weekly paclitaxel group were older and more frequently had angiosarcomas arising from the skin. In the doxorubicin group, 34 patients were evaluable for response: 2 (6%) had complete response, 8 (23.5%) had partial response, 10 (29.5%) had stable disease, and 14 (41%) had progressive disease. In the weekly paclitaxel group, 68 patients were evaluable for response: 9 (13%) had complete response, 27 (40%) had partial response, 20 (29.5%) had stable disease, and 12 (17.5%) had progressive disease. Objective responses to weekly paclitaxel were more frequent in cutaneous angiosarcomas, whereas tumor location did not impact response to doxorubicin. Median progression‐free survival (PFS) was 4.9 months (95% confidence interval [95% CI], 3.9‐6.0 months). Median overall survival (OS) was 8.5 months (95% CI, 6.4‐10.7 months). On multivariate analysis, ECOG performance status (PS) was the sole independent factor associated with PFS and OS.CONCLUSIONS: First‐line single‐agent doxorubicin and weekly paclitaxel seem to have similar efficacy in metastatic angiosarcomas. Cutaneous angiosarcomas respond favorably to weekly paclitaxel. Best supportive care should be considered in patients with poor PS. Cancer 2011. © 2011 American Cancer Society.Keywords
This publication has 32 references indexed in Scilit:
- Imatinib Mesylate in Advanced Dermatofibrosarcoma Protuberans: Pooled Analysis of Two Phase II Clinical TrialsJournal of Clinical Oncology, 2010
- Treatment with the mTOR inhibitor temsirolimus in patients with malignant PEComaAnnals of Oncology, 2010
- Clinical Activity of mTOR Inhibition With Sirolimus in Malignant Perivascular Epithelioid Cell Tumors: Targeting the Pathogenic Activation of mTORC1 in TumorsJournal of Clinical Oncology, 2010
- Transient response of cardiac angiosarcoma to paclitaxelEuropean Journal of Cancer Care, 2009
- Paclitaxel-Dependent Prolonged and Persistent Complete Remission Four Years from First Recurrence of Secondary Breast AngiosarcomaTumori Journal, 2009
- Response to paclitaxel in a radiotherapy-induced breast angiosarcomaActa Oncologica, 2009
- Angiosarcomas, a heterogeneous group of sarcomas with specific behavior depending on primary site: a retrospective study of 161 casesAnnals of Oncology, 2007
- Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective studyThe Lancet Oncology, 2007
- Molecularly targeted treatment for dermatofibrosarcoma protuberansSeminars in Oncology, 2004
- Phase II Clinical Investigation of Gemcitabine in Advanced Soft Tissue Sarcomas and Window Evaluation of Dose Rate on Gemcitabine Triphosphate AccumulationJournal of Clinical Oncology, 2001